NASDAQ:LTRN Lantern Pharma (LTRN) Stock Price, News & Analysis $1.55 -0.16 (-9.36%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$1.63 +0.08 (+5.16%) As of 09/18/2026 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Lantern Pharma Stock (NASDAQ:LTRN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lantern Pharma alerts:Sign Up Key Stats Today's Range$1.55▼$1.7550-Day Range$1.55▼$3.4652-Week Range$1.11▼$4.70Volume190,154 shsAverage Volume162,028 shsMarket Capitalization$19.81 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Lantern Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision cancer therapies. The company uses artificial intelligence and machine learning to analyze large datasets, identify biomarkers associated with treatment response, and guide the development or repurposing of oncology drug candidates. Lantern’s technology platform, known as RADR, is designed to support drug discovery, patient selection and clinical development by integrating genomic, clinical and drug-response data. Its pipeline has included investigational therapies for solid tumors and hematologic cancers, including programs aimed at non-small cell lung cancer and other difficult-to-treat malignancies. The company does not currently market an approved commercial product. Founded in 2013, Lantern Pharma is headquartered in Dallas, Texas, and became a publicly traded company in 2020. Panna Sharma serves as the company’s chief executive officer and is a member of its board of directors. Lantern’s activities are primarily centered on research, clinical development and collaborations within the biopharmaceutical and oncology sectors.AI Generated. May Contain Errors. Read More Lantern Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks14th Percentile Overall ScoreLTRN MarketRank™: Lantern Pharma scored higher than 14% of companies evaluated by MarketBeat, and ranked 852nd out of 895 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingLantern Pharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageLantern Pharma has only been the subject of 1 research reports in the past 90 days.Read more about Lantern Pharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Lantern Pharma is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lantern Pharma is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLantern Pharma has a P/B Ratio of 2.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Lantern Pharma's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.83% of the float of Lantern Pharma has been sold short.Short Interest Ratio / Days to CoverLantern Pharma has a short interest ratio ("days to cover") of 4.16.Change versus previous monthShort interest in Lantern Pharma has recently decreased by 18.53%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLantern Pharma does not currently pay a dividend.Dividend GrowthLantern Pharma does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.34 News SentimentLantern Pharma has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Lantern Pharma this week, compared to 2 articles on an average week.Search Interest3 people have searched for LTRN on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows2 people have added Lantern Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lantern Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders8.50% of the stock of Lantern Pharma is held by insiders.Percentage Held by Institutions28.62% of the stock of Lantern Pharma is held by institutions.Read more about Lantern Pharma's insider trading history. Receive LTRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lantern Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LTRN Stock News HeadlinesLantern Pharma Down Ahead of WebinarSeptember 17 at 2:51 PM | baystreet.caLantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23September 17 at 8:59 AM | finance.yahoo.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.September 20 at 1:00 AM | Behind the Markets (Ad)Lantern Pharma (LTRN) Q2 2026 Earnings Call TranscriptAugust 21, 2026 | finance.yahoo.comLantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 14, 2026 | businesswire.comLantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of ...August 4, 2026 | finance.yahoo.comLantern Pharma Spins Off Open-Medicine AI PlatformAugust 3, 2026 | tipranks.comLantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of MedicineAugust 3, 2026 | businesswire.comSee More Headlines LTRN Stock Analysis - Frequently Asked Questions How have LTRN shares performed this year? Lantern Pharma's stock was trading at $3.03 at the beginning of 2026. Since then, LTRN shares have decreased by 48.8% and is now trading at $1.55. How were Lantern Pharma's earnings last quarter? Lantern Pharma Inc. (NASDAQ:LTRN) announced its quarterly earnings data on Friday, August, 14th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.38) by $0.19. Read the conference call transcript. When did Lantern Pharma IPO? Lantern Pharma (LTRN) raised $28 million in an IPO on Thursday, June 11th 2020. The company issued 1,750,000 shares at a price of $15.00-$17.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO and Dougherty & Company and Paulson Investment Company were co-managers. Who are Lantern Pharma's major shareholders? Top institutional shareholders of Lantern Pharma include Empery Asset Management LP (6.60%), BlackRock Inc. (0.18%), Bank of New York Mellon Corp (0.17%) and Susquehanna International Group LLP (0.11%). Insiders that own company stock include D Jeffrey Keyser, Aaron GL Fletcher, Leslie W Kreis and Lee Troy Schalop. View institutional ownership trends. How do I buy shares of Lantern Pharma? Shares of LTRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lantern Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lantern Pharma investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Intel (INTC), Meta Platforms (META) and NIO (NIO). Company Calendar Last Earnings8/14/2026Today9/20/2026Investor update9/23/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 LTRN's financial health is in the Yellow zone, according to TradeSmith. LTRN has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:LTRN CIK1763950 Webwww.lanternpharma.com Phone972-277-1136FaxN/AEmployees16Year Founded2013Profitability EPS (Trailing Twelve Months)($1.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$17.12 million Net MarginsN/A Pretax MarginN/A Return on Equity-368.02% Return on Assets-148.62% Debt Debt-to-Equity RatioN/A Current Ratio1.96 Quick Ratio1.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.58 per share Price / Book2.67Miscellaneous Outstanding Shares12,780,000Free Float11,697,000Market Cap$19.81 million OptionableOptionable Beta2.30 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:LTRN) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredBefore Anthropic becomes impossible to ignore...Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...The Oxford Club | SponsoredThe Last Gold Bull Market?Former CIA and Pentagon official Jim Rickards says the current gold bull market could be its last. Investment ...Paradigm Press | SponsoredElon Musk to Trigger Next AI Wave on November 11th?Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredNo Wallstreet. No Advisor. No Problem.Savings accounts pay just 0.58 percent interest. Andy Howard, co-founder of Meridian Capital, says liquidity p...Awesomely | SponsoredThe end of AI data centers coming?Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantern Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantern Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
